NOVAVAX INC (NVAX) — SEC Financial Statements & Analysis

NOVAVAX INC (NVAX) is a biological products, (no diagnostic substances) company, incorporated in DE. NOVAVAX INC trades on Nasdaq as: NVAX. NOVAVAX INC (NVAX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, NOVAVAX INC carries a market cap of $1.55B, a P/E ratio of -6.26x, a P/B ratio of -8.13x, a P/S ratio of 3.75x, an enterprise value of $1.65B, and an EV/EBITDA multiple of -7.61x. On profitability, it posts a gross margin of 78.60%, an operating margin of -56.58%, a net margin of -59.87%, a Return on Equity (ROE) of 323.66%, and a Return on Assets (ROA) of -21.62%. Per share, it reports EPS of $-1.51, diluted EPS of $-1.51, free cash flow per share of $-0.26, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -61.64% year-over-year, net income growth of -158.59% year-over-year, and EPS growth of -157.68% year-over-year. On the balance sheet, it maintains a current ratio of 2.33x, a quick ratio of 2.23x, working capital of $440.52M, a debt-to-equity ratio of -6.01x, a debt ratio of 1.2, an interest coverage ratio of -10.69x, free cash flow of $-42.20M (TTM), and net debt of $95.45M. Figures sourced from SEC EDGAR.

Market Cap

$1.55B

P/E TTM

-6.26x

EPS TTM

$-1.51

P/B TTM

-8.13x

ROE TTM

323.66%

ROA TTM

-21.62%

Debt To Equity

-6.01x

Free Cash Flow TTM

$-42.20M

Net Revenue TTM Growth 1Y

-61.64%

Data as of 2026-06-30 · Source: SEC EDGAR